Developer docs
API playgroundTry for free, no card

Search company profiles

DMC Biotechnologies

Full company profile

uuid0000f14

Namestring
DMC Biotechnologies
Legal namestring
DMC Biotechnologies, Inc.
Websiteurl
dmcbio.com
Company typeenum
Private
Founded yearint
2014
Descriptiontext

DMC Biotechnologies is a US-based biomanufacturer founded in 2014 that produces sustainable, bio-based specialty chemicals using its proprietary Dynamic Metabolic Control™ precision fermentation platform. The technology is a standardized two-stage fermentation process that decouples microbial growth from production via controlled gene silencing and targeted proteolysis, enabling predictable scale-up from high-throughput screening (96-well plates) to commercial volumes and reducing microbe sensitivity to industrial conditions. DMC operates R&D facilities in Morrisville, North Carolina (Research Triangle Park, 9,500 sq ft, opened November 2023) and Boulder, Colorado, and licenses its core synthetic metabolic valve technology exclusively from Duke University.

The company commercializes KeyPura™ Myo-Inositol (launched May 2025) and KeyPura™ D-Chiro-Inositol (launched July 2025) for dietary supplements, nutraceuticals, and cosmetic actives, alongside L-Alanine and branched chain amino acids for nutrition and industrial chemical applications. Revenue is generated through direct enterprise sales and regional distribution partnerships—LBB Specialties in the United States and Canada, SCG Chemicals across ASEAN, plus strategic co-development agreements with Toyobo (Japan) and the Biotech Open Platform with Danone, Michelin, and Crédit Agricole Centre France in Clermont-Ferrand, France. Manufacturing is outsourced to partners including Conagen and EW Biotech (Leuna, Germany), where DMC demonstrated 85,000L commercial-scale L-alanine fermentation.

Short descriptiontext

DMC Biotechnologies is a US-based biomanufacturer that produces sustainable specialty chemicals—inositols, amino acids, and chemical intermediates—via its proprietary Dynamic Metabolic Control precision fermentation platform. It serves dietary supplement, cosmetic, and industrial chemical markets through direct sales and channel partners across North America, Europe, and Asia.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersDurham, United States
HQ citystring
Durham
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices2 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
precision fermentation, bio-based chemicals, specialty ingredients, inositol production, metabolic engineering
Industry3 codes
PRIMARYEUAAAIAK
Bio-based Pharmaceuticals, Nutraceuticals & Specialty Bioactives
Energy, Utilities & Environment/Bioenergy, Natural Gas & Biomass/Biorefining & Bio-based Chemicals (Co-products, Bioproducts)
SECONDARYHLAAAIAD
Synthetic Biology & Genetic Circuit Design Platforms (pathway engineering, chassis development)
Healthcare & Life Sciences/Biotechnology & Biologics/Biologic Drug Discovery Platforms (screening, antibody engineering, synthetic biology)
SECONDARYIMAMALAB
Biochemicals & Bio-based Platform Chemicals (cellulose sugars, lignin derivatives, organic acids)
NAICS code3 codes
  • Other Basic Organic Chemical Manufacturing32519
  • Biological Product (except Diagnostic) Manufacturing325414
  • All Other Basic Organic Chemical Manufacturing325199
SIC code3 codes
  • Industrial Organic Chemicals2860
  • Medicinal Chemicals & Botanical Products2833
  • Biological Products, (No Disgnostic Substances)2836
Product category
Bio-based specialty chemicals (precision fermentation ingredients)
GTM motion2 records

Each record includes

Type, Description, Source

Revenue model2 records
1Bio-based Specialty Chemical Sales
TypeOne Time License
Description

DMC generates revenue by selling proprietary fermentation-produced specialty chemicals and ingredients directly to manufacturers in nutrition, personal care, and industrial chemical markets. Revenue is derived from product sales of inositols, amino acids, and other bio-based chemicals.

dmcbio.com
2Product Distribution Partnerships
TypeTransaction Fee
Description

Revenue flows through distribution partnerships where DMC supplies products and partners handle regional distribution and sales. Examples include LBB Specialties for US/Canada and SCG for ASEAN markets.

dmcbio.com
Marketing channels5 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels3 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components6 values
Technology or R&D, Infrastructure, Personnel, Marketing or Sales, Supply Chain, Operations
Pricing details1 tier
1B2B ingredient sales with custom quotation
ModelOtherBilling cadenceMulti-year contract
Notes

Pricing determined through direct sales engagement; quote-based for bulk orders of KeyPura™ myo-inositol, D-chiro-inositol, L-alanine, and other bio-based chemicals

dmcbio.com
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Brand1 record
1KeyPura
Description

Brand name for DMC's fermented inositol products including myo-inositol and D-chiro-inositol for dietary supplements, nutraceuticals, and cosmetic actives

dmcbio.com
Core offering1 text field

DMC Biotechnologies designs and sells bio-based specialty chemicals produced via precision fermentation using its proprietary Dynamic Metabolic Control™ technology. Its commercial portfolio includes KeyPura Myo-Inositol and D-Chiro-Inositol for dietary supplements and cosmetic actives, plus L-Alanine and branched chain amino acids for nutrition and bio-based chemical applications. Products are sold as sustainable, fermentation-produced alternatives to conventionally manufactured ingredients for B2B brand owners and formulators.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 5 values shown
  • 90%+ CO2 emission reduction for L-alanine production compared to conventional supply chains
+4 more records
Product overview1 text field

DMC Biotechnologies is a U.S.-based biomanufacturer offering a portfolio of sustainably produced bio-based specialty chemicals through its proprietary Dynamic Metabolic Control precision fermentation technology platform. The company commercializes ingredients across three main markets: dietary supplements and nutraceuticals (KeyPura myo-inositol, KeyPura D-chiro-inositol), cosmetic actives, and bio-based chemicals and monomers (L-alanine, branched chain amino acids). The Dynamic Metabolic Control technology enables standardized, scalable, and predictable fermentation processes that decouple growth from production, allowing DMC to efficiently develop and manufacture multiple products with reduced environmental footprint. The company operates R&D facilities in Research Triangle Park, NC and Boulder, CO, with commercial production partnerships for global distribution.

Product and service4 records
1KeyPura Myo-Inositol
CategoryDietary supplements and nutraceutical ingredients
Description

Fermentation-produced myo-inositol for dietary supplements, functional foods, and cosmetic formulations. Supports cellular signaling, metabolic balance, and reproductive health, marketed to health-focused brand owners and formulators seeking a sustainable, naturally produced alternative to conventional myo-inositol.

2KeyPura D-Chiro-Inositol
CategoryDietary supplements and nutraceutical ingredients
Description

Fermentation-based D-chiro-inositol for women's health, testosterone support, and cardiometabolic health. Plays roles in insulin sensitivity and hormonal regulation, targeting nutraceutical and supplement formulators as an industry-first fermented alternative.

3L-Alanine
CategoryBio-based chemicals and intermediates
Description

Versatile chemical intermediate and nutritional supplement produced via precision fermentation. Provides a claimed 90%+ reduction in CO2 emissions compared to conventional chemical routes, supporting sustainable practices and supply chain resilience for nutrition and bio-based chemical applications.

4Branched Chain Amino Acids (BCAAs)
CategoryNutrition and bio-based amino acid ingredients
Description

Amino acids for human nutrition and other applications, developed and commercialized through DMC's fermentation platform for global markets, including distribution into the ASEAN region via SCG Chemicals.

Scale indicator5 records

Each record includes

Type, Value, Description, Source

Partnership7 partners
Strategic tierCoreTypeChannel Partner/ Reseller/ DistributorAnnounced on2026-04-07
Description

LBB Specialties serves as the distributor for DMC's KeyPura™ fermented myo-inositol and D-chiro-inositol in the United States and Canada. The partnership serves Human Nutrition, Food, Personal Care, and Life Science markets, bringing cleaner and more sustainable fermented inositol ingredients to North American customers.

2Toyobo
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2025-06-03
Description

Multi-year joint development agreement to develop sustainable, fermentation-produced high-volume chemical intermediates for use in essential materials. Toyobo brings chemical synthesis and biotechnology expertise along with global market access, while DMC contributes Dynamic Metabolic Control™ technology and metabolic engineering capabilities.

dmcbio.com
Strategic tierFlagshipTypeStrategic or Co-development PartnerAnnounced on2024-06-12
Description

Partnership to create the Biotech Open Platform at Center for Sustainable Materials - Parc Cataroux in Clermont-Ferrand, France. Initial investment of over 16 million euro in first phase to develop advanced fermentation processes at larger scale. Danone contributes food industry expertise and commitment to sustainable ingredients.

Strategic tierFlagshipTypeStrategic or Co-development PartnerAnnounced on2024-06-12
Description

Co-founder of the Biotech Open Platform at Parc Cataroux Center for Sustainable Materials. Michelin provides the facility infrastructure and supports development of bio-sourced materials as part of its sustainability commitment. Platform aims to accelerate scale-up of precision fermentation for materials innovation.

Strategic tierCoreTypeImplementation/ SI/ Consulting PartnerAnnounced on2021-04-21
Description

Manufacturing agreement for commercial production of DMC's first product, L-alanine. Conagen provides fermentation manufacturing capabilities to enable DMC to bring products to market without building own manufacturing infrastructure.

Strategic tierCoreTypeChannel Partner/ Reseller/ DistributorAnnounced on2021-03-15
Description

Agreement to bring DMC's L-Alanine and branched chain amino acids into ASEAN markets (Brunei, Cambodia, Indonesia, Laos, Malaysia, Myanmar, Philippines, Singapore, Thailand, Vietnam). SCG is a leading chemical company in Southeast Asia with wide regional distribution reach.

Strategic tierCoreTypeImplementation/ SI/ Consulting PartnerAnnounced on2021-03-15
Description

Service provider for process development, scale-up, and custom manufacturing of biotechnological processes. EW Biotech's facility in Leuna, Germany hosted DMC's commercial scale demonstration (85m3 fermentation) and downstream processing (6,000+ kg L-alanine purified).

Recent move8 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Market position
Competitive moat5 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers4 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment3 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile3 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
No
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature3 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles14 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds6 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors10 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

DMC Biotechnologies

Bio-based specialty chemicals (precision fermentation ingredients)dmcbio.com

DMC Biotechnologies is a US-based biomanufacturer that produces sustainable specialty chemicals—inositols, amino acids, and chemical intermediates—via its proprietary Dynamic Metabolic Control precision fermentation platform. It serves dietary supplement, cosmetic, and industrial chemical markets through direct sales and channel partners across North America, Europe, and Asia.

What DMC Biotechnologies does

DMC Biotechnologies is a US-based biomanufacturer founded in 2014 that produces sustainable, bio-based specialty chemicals using its proprietary Dynamic Metabolic Control™ precision fermentation platform. The technology is a standardized two-stage fermentation process that decouples microbial growth from production via controlled gene silencing and targeted proteolysis, enabling predictable scale-up from high-throughput screening (96-well plates) to commercial volumes and reducing microbe sensitivity to industrial conditions. DMC operates R&D facilities in Morrisville, North Carolina (Research Triangle Park, 9,500 sq ft, opened November 2023) and Boulder, Colorado, and licenses its core synthetic metabolic valve technology exclusively from Duke University.

The company commercializes KeyPura™ Myo-Inositol (launched May 2025) and KeyPura™ D-Chiro-Inositol (launched July 2025) for dietary supplements, nutraceuticals, and cosmetic actives, alongside L-Alanine and branched chain amino acids for nutrition and industrial chemical applications. Revenue is generated through direct enterprise sales and regional distribution partnerships—LBB Specialties in the United States and Canada, SCG Chemicals across ASEAN, plus strategic co-development agreements with Toyobo (Japan) and the Biotech Open Platform with Danone, Michelin, and Crédit Agricole Centre France in Clermont-Ferrand, France. Manufacturing is outsourced to partners including Conagen and EW Biotech (Leuna, Germany), where DMC demonstrated 85,000L commercial-scale L-alanine fermentation.

DMC Biotechnologies firmographics

Firmographics
Name
DMC Biotechnologies
Legal name
DMC Biotechnologies, Inc.
Website
https://dmcbio.com
Company type
Private
Founded year
2014
Operating status
Operating
Headcount range
11–50 employees
Short description
DMC Biotechnologies is a US-based biomanufacturer that produces sustainable specialty chemicals—inositols, amino acids, and chemical intermediates—via its proprietary Dynamic Metabolic Control precision fermentation platform. It serves dietary supplement, cosmetic, and industrial chemical markets through direct sales and channel partners across North America, Europe, and Asia.
Ownership category
akta.pro rank

DMC Biotechnologies industry classification

Industry
Product category
Bio-based specialty chemicals (precision fermentation ingredients)
NAICS
Other Basic Organic Chemical Manufacturing (32519), Biological Product (except Diagnostic) Manufacturing (325414), All Other Basic Organic Chemical Manufacturing (325199)
SIC
Industrial Organic Chemicals (2860), Medicinal Chemicals & Botanical Products (2833), Biological Products, (No Disgnostic Substances) (2836)
akta.pro industry
PRIMARYEUAAAIAK
Bio-based Pharmaceuticals, Nutraceuticals & Specialty Bioactives
Energy, Utilities & Environment/Bioenergy, Natural Gas & Biomass/Biorefining & Bio-based Chemicals (Co-products, Bioproducts)
SECONDARYHLAAAIAD
Synthetic Biology & Genetic Circuit Design Platforms (pathway engineering, chassis development)
Healthcare & Life Sciences/Biotechnology & Biologics/Biologic Drug Discovery Platforms (screening, antibody engineering, synthetic biology)
SECONDARYIMAMALAB
Biochemicals & Bio-based Platform Chemicals (cellulose sugars, lignin derivatives, organic acids)

Keywords

  • Precision fermentation
  • Bio-based chemicals
  • Specialty ingredients
  • Inositol production
  • Metabolic engineering

Where DMC Biotechnologies is headquartered

Location

Headquarters

HQ city
Durham
HQ country
United States
HQ region
North America

Offices2 records

Markets served

DMC Biotechnologies business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Technology or R&D, Infrastructure, Personnel, Marketing or Sales, Supply Chain, Operations

Revenue model

  1. Bio-based Specialty Chemical Sales: DMC generates revenue by selling proprietary fermentation-produced specialty chemicals and ingredients directly to manufacturers in nutrition, personal care, and industrial chemical markets. Revenue is derived from product sales of inositols, amino acids, and other bio-based chemicals.
  2. Product Distribution Partnerships: Revenue flows through distribution partnerships where DMC supplies products and partners handle regional distribution and sales. Examples include LBB Specialties for US/Canada and SCG for ASEAN markets.

Pricing tiers

ModelBillingPrice
OtherMulti-year contractB2B ingredient sales with custom quotation

Go-to-market motion2 records

Distribution channels3 records

Marketing channels5 records

DMC Biotechnologies product offering

Product offering

Core offering

DMC Biotechnologies designs and sells bio-based specialty chemicals produced via precision fermentation using its proprietary Dynamic Metabolic Control™ technology. Its commercial portfolio includes KeyPura Myo-Inositol and D-Chiro-Inositol for dietary supplements and cosmetic actives, plus L-Alanine and branched chain amino acids for nutrition and bio-based chemical applications. Products are sold as sustainable, fermentation-produced alternatives to conventionally manufactured ingredients for B2B brand owners and formulators.

Product overview

DMC Biotechnologies is a U.S.-based biomanufacturer offering a portfolio of sustainably produced bio-based specialty chemicals through its proprietary Dynamic Metabolic Control precision fermentation technology platform. The company commercializes ingredients across three main markets: dietary supplements and nutraceuticals (KeyPura myo-inositol, KeyPura D-chiro-inositol), cosmetic actives, and bio-based chemicals and monomers (L-alanine, branched chain amino acids). The Dynamic Metabolic Control technology enables standardized, scalable, and predictable fermentation processes that decouple growth from production, allowing DMC to efficiently develop and manufacture multiple products with reduced environmental footprint. The company operates R&D facilities in Research Triangle Park, NC and Boulder, CO, with commercial production partnerships for global distribution.

Differentiator

Problem solved

Functional benefit

Brands

  • KeyPura: Brand name for DMC's fermented inositol products including myo-inositol and D-chiro-inositol for dietary supplements, nutraceuticals, and cosmetic actives

Products and services

  • KeyPura Myo-Inositol Fermentation-produced myo-inositol for dietary supplements, functional foods, and cosmetic formulations. Supports cellular signaling, metabolic balance, and reproductive health, marketed to health-focused brand owners and formulators seeking a sustainable, naturally produced alternative to conventional myo-inositol.
  • KeyPura D-Chiro-Inositol Fermentation-based D-chiro-inositol for women's health, testosterone support, and cardiometabolic health. Plays roles in insulin sensitivity and hormonal regulation, targeting nutraceutical and supplement formulators as an industry-first fermented alternative.
  • L-Alanine Versatile chemical intermediate and nutritional supplement produced via precision fermentation. Provides a claimed 90%+ reduction in CO2 emissions compared to conventional chemical routes, supporting sustainable practices and supply chain resilience for nutrition and bio-based chemical applications.
  • Branched Chain Amino Acids (BCAAs) Amino acids for human nutrition and other applications, developed and commercialized through DMC's fermentation platform for global markets, including distribution into the ASEAN region via SCG Chemicals.

Quantifiable outcome

  • 90%+ CO2 emission reduction for L-alanine production compared to conventional supply chains
  • +4 more outcomes

Companies that use DMC Biotechnologies

Customer profile

Named customers4 records

Segments3 records

Ideal customer profiles3 records

DMC Biotechnologies technology and API

Technology

Technology focussed No

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature3 records

DMC Biotechnologies partnerships and signals

Strategic signal

Partnerships

Seven partnerships are on record, tiered core and flagship.

  • LBB SpecialtiescoreChannel Partner/ Reseller/ Distributor · 7 April 2026LBB Specialties serves as the distributor for DMC's KeyPura™ fermented myo-inositol and D-chiro-inositol in the United States and Canada. The partnership serves Human Nutrition, Food, Personal Care, and Life Science markets, bringing cleaner and more sustainable fermented inositol ingredients to North American customers.
  • ToyobocoreStrategic or Co-development Partner · 3 June 2025Multi-year joint development agreement to develop sustainable, fermentation-produced high-volume chemical intermediates for use in essential materials. Toyobo brings chemical synthesis and biotechnology expertise along with global market access, while DMC contributes Dynamic Metabolic Control™ technology and metabolic engineering capabilities.
  • DanoneflagshipStrategic or Co-development Partner · 12 June 2024Partnership to create the Biotech Open Platform at Center for Sustainable Materials - Parc Cataroux in Clermont-Ferrand, France. Initial investment of over 16 million euro in first phase to develop advanced fermentation processes at larger scale. Danone contributes food industry expertise and commitment to sustainable ingredients.
  • MichelinflagshipStrategic or Co-development Partner · 12 June 2024Co-founder of the Biotech Open Platform at Parc Cataroux Center for Sustainable Materials. Michelin provides the facility infrastructure and supports development of bio-sourced materials as part of its sustainability commitment. Platform aims to accelerate scale-up of precision fermentation for materials innovation.
  • ConagencoreImplementation/ SI/ Consulting Partner · 21 April 2021Manufacturing agreement for commercial production of DMC's first product, L-alanine. Conagen provides fermentation manufacturing capabilities to enable DMC to bring products to market without building own manufacturing infrastructure.
  • SCG ChemicalscoreChannel Partner/ Reseller/ Distributor · 15 March 2021Agreement to bring DMC's L-Alanine and branched chain amino acids into ASEAN markets (Brunei, Cambodia, Indonesia, Laos, Malaysia, Myanmar, Philippines, Singapore, Thailand, Vietnam). SCG is a leading chemical company in Southeast Asia with wide regional distribution reach.
  • EW BiotechcoreImplementation/ SI/ Consulting Partner · 15 March 2021Service provider for process development, scale-up, and custom manufacturing of biotechnological processes. EW Biotech's facility in Leuna, Germany hosted DMC's commercial scale demonstration (85m3 fermentation) and downstream processing (6,000+ kg L-alanine purified).

Scale indicators5 records

Recent moves8 records

Expansion highlights6 records

DMC Biotechnologies competitors and assessment

Company assessment

Market position

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

DMC Biotechnologies social profiles

Digital presence

DMC Biotechnologies financial estimates

Financial estimate

Revenue estimate

Valuation estimate

DMC Biotechnologies leadership team

Management profile

Number of profiles

Profiles14 records

DMC Biotechnologies funding detail

Funding detail

Funding overview

Funding rounds6 records

Investors10 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

DMC Biotechnologies M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about DMC Biotechnologies

What does DMC Biotechnologies do?

DMC Biotechnologies designs and sells bio-based specialty chemicals produced via precision fermentation using its proprietary Dynamic Metabolic Control™ technology. Its commercial portfolio includes KeyPura Myo-Inositol and D-Chiro-Inositol for dietary supplements and cosmetic actives, plus L-Alanine and branched chain amino acids for nutrition and bio-based chemical applications. Products are sold as sustainable, fermentation-produced alternatives to conventionally manufactured ingredients for B2B brand owners and formulators.

Is DMC Biotechnologies a public or private company?

DMC Biotechnologies is a private company. It is classified as venture growth investor backed and is currently operating.

When was DMC Biotechnologies founded?

DMC Biotechnologies was founded in 2014. It employs 11 to 50 people.

Where is DMC Biotechnologies based?

DMC Biotechnologies is headquartered in Durham, United States, in the North America region.

How does DMC Biotechnologies make money?

Two revenue lines are on record. Bio-based Specialty Chemical Sales are the primary driver. The others are product Distribution Partnerships.

Does DMC Biotechnologies have an API?

No public API is recorded for DMC Biotechnologies.

What industry is DMC Biotechnologies in?

DMC Biotechnologies's product category is Bio-based specialty chemicals (precision fermentation ingredients). Its primary akta.pro industry code is EUAAAIAK, Bio-based Pharmaceuticals, Nutraceuticals & Specialty Bioactives, with a secondary code of HLAAAIAD, Synthetic Biology & Genetic Circuit Design Platforms (pathway engineering, chassis development). Its NAICS code is 32519 and its SIC code is 2860.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
EIN PresswireDMC Biotechnologies Secures $18 Million to Accelerate Growth of Health Ingredients BusinessDMC Biotechnologies secured $18 million to accelerate commercialization of its KeyPura™ health ingredients portfolio. The funding will support customer adoption, distribution expansion, and development of new bioactive ingredients. The company expects to direct the investment toward continued commercialization and future product development.EIN PresswireDMC Biotechnologies Secures $18 Million to Accelerate Growth of Health Ingredients BusinessDMC Biotechnologies secured $18 million to accelerate commercialization of its KeyPura™ health ingredients portfolio. The funding will support customer adoption, distribution expansion, and development of new bioactive ingredients. The company expects to direct the investment toward continued commercialization and future product development.pharmaphorumLongevity as the new health paradigm: The control systemValerio Nannini argues that the health industry is shifting from aesthetic fitness to a 'longevity economy' focused on extending healthspan, positioning nutrition as the critical biological control system. The article outlines how metabolic health and specific metrics like VO2 max are becoming central to this paradigm, with an upcoming panel in Berlin featuring executives from Phenotap, Savor Health, DMC Biotechnologies, Novonesis, Momentum Partners, and Technogym.PR NewswireLBB Specialties and DMC Biotechnologies Partner to Bring Fermented Inositols to the U.S. MarketLBB Specialties, a North American specialty chemicals distributor, announced a partnership with DMC Biotechnologies to serve as the U.S. and Canada distributor of DMC's KeyPura fermented myo-inositol and D-chiro-inositol ingredients produced through precision fermentation. The fermented inositols target Human Nutrition, Food, Personal Care, and Life Science markets, offering bio-identical compounds with greater purity and lower environmental footprint than traditional chemical production. The agreement strengthens LBB Specialties' portfolio of functional and sustainable ingredient technologies for the North American market.NewswireLBB Specialties and DMC Biotechnologies Partner to Bring Fermented Inositols to the U.S. MarketLBB Specialties announced a partnership with DMC Biotechnologies to serve as the exclusive U.S. and Canada distributor of DMC's KeyPura fermented myo-inositol and D-chiro-inositol ingredients. The products are produced through DMC's precision fermentation technology and target Human Nutrition, Food, Personal Care, and Life Science markets. The collaboration positions both companies to meet growing demand for sustainable, bio-identical ingredients with health applications including hormonal balance, metabolic health, and reproductive health.EIN PresswireLBB Specialties and DMC Biotechnologies Partner to Bring Fermented Inositols to the U.S. MarketLBB Specialties announced a partnership with DMC Biotechnologies to serve as the exclusive U.S. and Canada distributor of DMC's KeyPura fermented myo-inositol and D-chiro-inositol ingredients. The ingredients, produced through DMC's proprietary precision fermentation technology, target the Human Nutrition, Food, Personal Care, and Life Science markets, offering a more sustainable and bio-identical alternative to traditional chemical production methods. The agreement strengthens LBB Specialties' portfolio of functional and sustainable ingredient technologies while expanding DMC's market reach.PR NewswireLBB Specialties and DMC Biotechnologies Partner to Bring Fermented Inositols to the U.S. MarketLBB Specialties announced a partnership with DMC Biotechnologies to serve as the exclusive U.S. and Canada distributor of DMC's KeyPura fermented myo-inositol and D-chiro-inositol ingredients. These next-generation ingredients are produced through DMC's proprietary precision fermentation technology and target the Human Nutrition, Food, Personal Care, and Life Science markets. The agreement strengthens LBB Specialties' portfolio of functional and sustainable ingredient technologies while expanding DMC's commercial reach across North America.Chemical & Engineering NewsBiobased chemicals face a fraught yearThe biobased chemicals and fuels industry faces a tumultuous 2026 as uncertain US policy environments and reduced cleantech support are expected to push investment overseas while causing some startups to falter. Several companies, including DMC Biotechnologies, Gevo, and Twelve, are nonetheless advancing new production methods and scaling up operations despite the challenging environment. Industry observers predict that China and Europe will capture more bioeconomy investment as the US policy landscape remains inhospitable for cleantech.DmcbioDMC BiotechnologiesDMC Biotechnologies is promoting its precision fermentation technology platform, Dynamic Metabolic Control™, to produce sustainable bio-based specialty chemicals. The company highlights the environmental benefits of its L-alanine production, claiming a potential reduction in CO2 emissions by over 90% compared to conventional methods.SynBioBetaDMC Launches Fermented Myo-Inositol, a Cleaner and More Sustainable Alternative, Benefiting Metabolic, Reproductive, and Infant Health MarketsDMC Biotechnologies launched fermented myo-inositol, a naturally produced ingredient for health brands. The fermentation process offers higher purity and sustainability compared to traditional chemical synthesis. The company plans to introduce a second ingredient later this year.